These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 29040782)

  • 41. Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells.
    Thomas CY; Chouinard M; Cox M; Parsons S; Stallings-Mann M; Garcia R; Jove R; Wharen R
    Int J Cancer; 2003 Mar; 104(1):19-27. PubMed ID: 12532415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular, histopathological, and genomic variants of glioblastoma.
    Karsy M; Huang T; Kleinman G; Karpel-Massler G
    Front Biosci (Landmark Ed); 2014 Jun; 19(7):1065-87. PubMed ID: 24896337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
    N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
    Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
    Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current and emerging EGFR therapies for glioblastoma.
    Artene SA; Tuţă C; Dragoi A; Alexandru O; Stefana Oana P; Tache DE; Dănciulescu MM; Boldeanu MV; Siloşi CA; Dricu A
    J Immunoassay Immunochem; 2018; 39(1):1-11. PubMed ID: 29308973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
    Chen YM
    J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors.
    Cheng Y; Ng HK; Ding M; Zhang SF; Pang JC; Lo KW
    J Neuropathol Exp Neurol; 1999 Feb; 58(2):120-8. PubMed ID: 10029095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.
    Stec WJ; Rosiak K; Siejka P; Peciak J; Popeda M; Banaszczyk M; Pawlowska R; Treda C; Hulas-Bigoszewska K; Piaskowski S; Stoczynska-Fidelus E; Rieske P
    Oncotarget; 2016 May; 7(22):31907-25. PubMed ID: 27004406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).
    Zhong J; Li L; Wang Z; Bai H; Gai F; Duan J; Zhao J; Zhuo M; Wang Y; Wang S; Zang W; Wu M; An T; Rao G; Zhu G; Wang J
    J Thorac Oncol; 2017 Dec; 12(12):1766-1778. PubMed ID: 28818608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
    Raizer JJ
    J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The hydroxyurea-induced loss of double-minute chromosomes containing amplified epidermal growth factor receptor genes reduces the tumorigenicity and growth of human glioblastoma multiforme.
    Canute GW; Longo SL; Longo JA; Shetler MM; Coyle TE; Winfield JA; Hahn PJ
    Neurosurgery; 1998 Mar; 42(3):609-16. PubMed ID: 9526995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glioblastoma: pathology, molecular mechanisms and markers.
    Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
    Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.
    Shan L; Wang Z; Guo L; Sun H; Qiu T; Ling Y; Li W; Li L; Liu X; Zheng B; Lu N; Ying J
    Lung Cancer; 2015 Sep; 89(3):337-42. PubMed ID: 26141217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
    Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
    Mesbahi Y; Zekri A; Ahmadian S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Eur J Pharmacol; 2018 Feb; 820():274-285. PubMed ID: 29274334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.